Clinical trial · Interventional
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
A Prospective Observational Study of Patients With Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): poor accrual
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and fludeoxyglucose F 18 positron emission tomography (\^18FDG-PET) may help diagnose solitary plasmacytoma. PURPOSE: This clinical trial is studying MRI and \^18FDG-PET to see how well they work in diagnosing patients with solitary plasmacytoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Plasmacytoma | Plasmacytoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| magnetic resonance imaging | Procedure | — | UNRESOLVED |
| positron emission tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- MRI and PET
- description
- Magnetic resonance imaging and positron emission tomography
- interventionNames
- Procedure: magnetic resonance imaging
- Procedure: positron emission tomography
Primary outcomes (1)
- measure
- proportion of patients misclassified as solitary plasmacytoma
- timeFrame
- 2 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed solitary plasmacytoma of 1 of the following types: * Solitary bone plasmacytoma * Extraosseus solitary plasmacytoma * Bone marrow plasmacytosis \< 10% within the past 4 weeks * Low serum and/or urine M-protein meeting ≥ 1 of the following criteria: * Serum IgG \< 3.5 g/dL * Serum IgA \< 2.0 g/dL * Urine M-protein (kappa or lambda) \< 1.0 g/24 hours * No lytic lesions on skeletal survey other than a single lesion associated with solitary plasmacytoma within the past 4 weeks PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Zubrod 0-2 Life expectancy * Not specified Hematopoietic * Hemoglobin ≥ 10 g/dL\* AND/OR * No hemoglobin 2 g/dL \< lower limit of normal\* (LLN) NOTE: \*Patients with a history of hemoglobin \< 10 g/dL AND/OR \< 2 g/dL \< LLN that has corrected or improved after epoetin alfa but requires continued treatment with epoetin alfa are not eligible Hepatic * Not specified Renal * Calcium ≤ 10.5 mg/dL OR * Calcium normal * Creatinine ≤ 2 mg/dL Other * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or stage I or II cancer that is currently in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * No prior high-dose steroids except to relieve neurological compromise Radiotherapy * Prior localized radiotherapy for myeloma allowed * Concurrent radiotherapy allowed Surgery * Prior surgery for myeloma allowed Other * No other prior therapy for myeloma * Concurrent enrollment in protocol SWOG-S0309 (Myeloma Specimen Repository) allowed
References
Publications (0)
Data not yet available